【导读】上午A股三大指数集体大涨，半导体、保险板块大涨，脑机接口概念股掀"涨停潮" 大家好，今天是2026年第一个交易日，基金君和你继续关注市场行情！ 1月5日上午，A股三大股指高开高走，沪指重返4000点，超4000只个股上涨，近百只个股涨停。截至午间收盘，沪指报4011.45点，涨1.07%，深证成指涨 1.87%，创业板指涨2.15%。 沪深两市半日成交额达1.64万亿元，较上个交易日放量3238亿元。个股涨多跌少，全市场共4064只个股上涨，99只个股涨停，有1236只个股下跌。 个股方面，翔宇医疗、冠昊生物（300238）、美好医疗（301363）、爱朋医疗（300753）、乐普医疗（300003）录得20cm涨停，三七互娱（002555）、 创新医疗（002173）、航天长峰（600855）录得10cm涨停。 | 代码 | 名称 | 现价 | 涨跌幅 ▼ | 总市值1 | 年初至今涨跌幅 | | --- | --- | --- | --- | --- | --- | | 688626 | 翔宇医疗 | 72.60 | 20.00% | 116亿 | 20.00% | | 300238 | 冠昊生物 ...

◎记者 时娜 上市公司的回购增持热潮持续至2026年。2026年1月4日，东诚药业、世纪华通等上市公司发布回购股份 计划，宁德时代、美的集团、潍柴动力、蓝思科技等多家深市龙头公司也披露了回购进展情况，英派斯 等公司披露增持计划实施情况，以"真金白银"传递信心，夯实公司价值投资基础。此外，多家上市公司 近日宣布向投资者派发"大红包"。 股份回购是上市公司优化股权结构、提升股东回报的重要抓手。2026年伊始，便有深市上市公司发布股 份回购计划。 东诚药业1月4日公告，计划以集中竞价交易方式回购股份，金额不低于1亿元（含），不超过2亿元 （含），用于实施股权激励和/或员工持股计划。回购价格不超过18.00元/股。 2025年以来，深市上市公司积极回应号召、立足自身发展，持续掀起"真金白银"的回购、增持、分红热 潮，多措并举提升投资者回报，为资本市场健康发展注入强劲动力。 上市公司下"红包雨" 据上海证券报记者不完全统计，2025年12月31日至2026年1月4日晚，仅深市就有15家公司披露半年度或 三季度分红实施公告，相关分红将于2026年1月陆续到账。 其中，天赐材料公告，公司2025年前三季度利润分配预案已获2 ...

Summary of Pharmaceutical Industry Conference Call Industry Overview - The pharmaceutical industry is projected to rank 18th among 31 primary industries in 2024, with an increase of 11.94%. However, the overall performance has been average, with a recent decline of 2% ranking it 28th among the same industries [2][4]. - The innovative drug sector is showing signs of recovery after four years of a bear market, while other sectors are gradually overcoming negative impacts from cost control measures [3][4]. Key Insights Innovative Drugs - Despite a low market sentiment, the innovative drug sector is experiencing continuous improvements, with significant industry benefits such as the $100 million upfront payment for Zai Lab's CD3DL3 tri-antibody product licensed to AbbVie [3][5]. - Recommended companies for investment in the innovative drug space include Innovent Biologics, China National Pharmaceutical Group, and Lepu Biopharma, all of which have low-risk clinical data or licensing agreements [6]. Medical Devices - The medical device sector is nearing the end of inventory destocking, with expectations for improved quarterly performance in 2026. Significant growth in bidding volumes is anticipated [3][6]. - Key companies to watch include Aohua, Carrier, Mindray, and United Imaging, particularly in high-value consumables like electrophysiology and neurosurgery [6][7]. Traditional Chinese Medicine (TCM) - The TCM sector is expected to recover gradually from Q2 2025 to Q1 2026, with hospital-based TCM likely to lead the recovery [9][10]. - The impact of the "15th Five-Year Plan" and the addition of essential drug lists are seen as potential benefits for the sector [9][11]. CRO and API Sectors - The CRO sector is performing well, with companies like WuXi AppTec and Pharmaron expected to see continued growth in orders and revenue [12]. - The API sector is closely tied to manufacturing trends, with companies like Tianyu Co., Starlight, and Tonghe expected to reach performance inflection points by 2026 [12][13]. Performance Expectations for 2025 - The pharmaceutical industry is expected to show a mixed performance in 2025, with notable growth in specific companies: - New Biotech's innovative product revenue is projected to grow over 50% - Yuan Dong's net profit growth is expected to be between 15%-20% - Tonghua Dongbao's revenue growth is anticipated at 40%-50% [15]. Conclusion - The pharmaceutical industry is navigating a complex landscape with varying performance across sectors. The innovative drug and medical device sectors present significant investment opportunities, while TCM is on the cusp of recovery. The CRO and API sectors are also positioned for growth, making them attractive for investors looking for potential returns in the coming years.

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance that exceeds the market by more than 5% over the next six months [29]. Core Insights - The report highlights that the national government will continue to support the renewal of medical equipment in 2026, which is expected to drive demand in the medical device sector. The focus is on high-end equipment and companies with significant performance improvements and international expansion, such as Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical [3]. - The report emphasizes the optimization of application conditions and review processes for equipment renewal projects, aiming to lower investment thresholds and enhance support for small and medium-sized enterprises [3]. - The ongoing policy for equipment renewal is anticipated to sustain a favorable bidding environment for medical devices, with a gradual improvement in performance as inventory clears [3]. Summary by Sections Industry Overview - The report discusses the government's announcement on December 30, 2025, regarding large-scale equipment renewal and the inclusion of various sectors, including healthcare, in the support framework for 2026 [3]. - It outlines the measures to improve the application process for equipment renewal, including stricter requirements for equipment depreciation and minimum usage periods [3]. Investment Opportunities - The report suggests focusing on companies that are expected to show significant performance improvements and have a leading international presence in the medical device sector [3]. - Specific companies recommended for investment include Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical, which are well-positioned to benefit from the anticipated demand for high-end medical equipment [3]. Market Performance - The medical sector has experienced a decline, with a reported drop of 2.06% in the last week, ranking 25th among 28 industries [8][18]. - The report notes that the medical device market is under pressure in the short term due to policy impacts, but improvements are expected as companies innovate and expand internationally [5].

Core Insights - Since 2025, companies listed on the Shenzhen Stock Exchange have actively engaged in share buybacks and increases, with a total of 424 disclosed plans amounting to a maximum of 114.25 billion yuan, reflecting their confidence in long-term development and enhancing investor trust [1][3]. Group 1: Overall Trends - The overall trend in 2025 shows a significant increase in willingness for share buybacks and increases, characterized by high intent, considerable scale, and industry concentration [2][3]. - Out of the 424 disclosed plans, 288 were buyback plans with a maximum amount of 82.725 billion yuan, while 136 were increase plans with a maximum of 31.521 billion yuan [3]. Group 2: Industry Focus - Key industries leading the buyback efforts include electronics, biomedicine, machinery, and power equipment, accounting for 40.97% of total buybacks, while biomedicine, machinery, basic chemicals, and home appliances lead in increases, making up 37.78% [3]. - The buyback and increase activities are seen as mechanisms for companies to optimize their equity structure and enhance shareholder returns, contributing to market stability and liquidity [3]. Group 3: Leading Companies - Leading companies in various sectors have played a pivotal role in guiding market trends through substantial buybacks and increases, establishing benchmarks and stabilizing expectations [4][5]. - Midea Group has executed a buyback plan exceeding 10 billion yuan, aimed at reducing registered capital and implementing employee stock ownership plans, thereby enhancing shareholder equity [5]. - Contemporary Amperex Technology Co., Ltd. (CATL) plans to buy back shares totaling between 4 billion and 8 billion yuan, reflecting its commitment to value creation [5]. Group 4: Market Dynamics - The buyback activities of leading companies are seen as a reflection of rational recognition of their value and the gradual emergence of long-term investment value in the capital market [6]. - The ongoing market reforms and regulatory improvements are expected to sustain the positive momentum of buybacks and increases, providing robust support for the high-quality development of the capital market [6].

【#深市上市公司回购增持活跃# 2025年披露计划超400单】#去年深市披露回购增持计划超400单# 近年来，在政策推动、企业积极向市场传递发展信心等因素下，深市上市公司回购股份、重要股东增持 等行为持续常态化。 据统计，2025年全年深市共披露回购与增持计划424单，其中回购计划288单，回购金额上限达827.25亿 元；增持计划136单，增持金额上限达315.21亿元。 自回购增持专项贷款落地以来，383家公司及主要股东取得股票回购增持专项贷贷款承诺函，贷款额度 共计829.81亿元。 从行业分布看，电子、生物医药、机械设备、电力设备领域公司成为回购主力军，合计占比达 40.97%，生物医药、机械设备、基础化工、家用电器领域公司成为增持先锋队，合计占比达37.78%， 充分体现了相关实体产业对发展前景的乐观预期。 各行业龙头企业充分发挥"压舱石"作用，以大额回购、持续增持的实际行动引领市场风向。 家用电器龙头企业美的集团基于对公司未来发展前景的信心和公司价值的认可，先后推出二期回购计 划，用于注销减少注册资本、实施股权激励或员工持股计划，截至目前，公司累计回购超100亿元，既 提升股东权益，又绑定核心团队 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Viewpoints - The pharmaceutical and biotechnology sector experienced a weekly return of -2.06%, ranking 28th among 31 primary sub-industry indices, with the medical services sub-sector performing the best at -1.40% [3][9] - Emerging industries such as brain-computer interfaces, robotics, and AI applications are highlighted as key areas of focus for investment in 2026, alongside state-owned enterprise reforms as part of the "14th Five-Year Plan" [3][9] - Long-term investment themes include innovation and international expansion, with recommendations to focus on high-end medical devices and innovative drug supply chains [3][9] Summary by Sections 1. Industry Weekly Viewpoints - The medical services sub-sector had the highest weekly return, while the pharmaceutical commercial sub-sector ranked sixth with a return of -2.68% [9] - The report emphasizes the importance of new industries and state-owned enterprise reforms for investment opportunities in 2026 [3][9] 2. Pharmaceutical Sector Performance and Valuation - The pharmaceutical and biotechnology industry index had a recent one-month return of -2.97%, ranking 29th among primary sub-indices [11] - The current PE (TTM) for the pharmaceutical and biotechnology industry is 28.59 times, slightly below the five-year historical average of 28.62 times [15][18] 3. Market Tracking - The medical services sub-sector showed the smallest weekly decline, while it also had the highest monthly return of 1.91% [28] - The report provides detailed performance metrics for various sub-sectors, indicating a mixed performance across the board [25][28] 4. Industry and Company Dynamics - Recent policy developments include the implementation of a unified basic medical insurance management procedure in Guangdong Province, effective February 1, 2026 [35] - Significant news includes the approval of new drugs and clinical trials by various companies, indicating ongoing innovation in the sector [36][37]

整体态势：意愿持续高涨 重点行业聚力 2025年，深市上市公司回购增持计划不断涌现，整体呈现"意愿高涨、规模可观、行业集 中"的鲜明特征。 截至2025年12月31日，深市上市公司共披露的424单回购增持计划中，回购计划288单，回 购金额上限达827.25亿元；增持计划136单，增持金额上限达315.21亿元。自回购增持专项 贷款落地以来，383家公司及主要股东取得股票回购增持专项贷贷款承诺函，贷款额度共计 829.81亿元。 从行业分布看，电子、生物医药、机械设备、电力设备领域公司成为回购主力军，合计占比 达40.97%，生物医药、机械设备、基础化工、家用电器领域公司成为增持先锋队，合计占比 达37.78%，充分体现了相关实体产业对发展前景的乐观预期。 2025年以来，深市上市公司积极回应号召、立足自身发展，持续掀起"真金白银"的回购 增持热潮。数据显示，截至2025年12月31日，深市上市公司共披露回购增持计划424 单，回购增持金额上限达1142.46亿元。 这不仅彰显了公司对自身价值的认可、对长期发展前景的坚定信心，更向市场传递出积极稳 健的信号、增强投资者信心，为资本市场健康发展注入强劲动力。 2 ...

Core Viewpoint - The active share buyback and increase in holdings by listed companies since 2025 reflect their recognition of intrinsic value and confidence in long-term development, sending positive signals to the market and enhancing investor confidence, thus injecting strong momentum into the healthy development of the capital market [1][2]. Group 1: Share Buyback and Increase in Holdings - In 2022, a total of 424 share buyback and increase plans were disclosed by listed companies in the Shenzhen market, including 288 buyback plans with a maximum amount of 82.725 billion yuan and 136 increase plans with a maximum amount of 31.521 billion yuan [2]. - Major companies such as CATL, Midea Group, Weichai Power, and Lens Technology have announced their buyback progress, with CATL repurchasing 15.9908 million shares for a total of 4.386 billion yuan, Midea Group repurchasing 20.5646 million shares for 1.51 billion yuan, Weichai Power repurchasing 50.2525 million shares for 0.761 billion yuan, and Lens Technology repurchasing 740.96 million shares for 0.215 billion yuan [1]. Group 2: Industry Trends and Insights - The buyback and increase plans are concentrated in key industries, with electronics, biomedicine, machinery, and power equipment companies accounting for 40.97% of the total, while biomedicine, machinery, basic chemicals, and home appliances account for 37.78% of the increase plans, indicating optimistic expectations for future development in these sectors [2]. - Leading companies in various industries are playing a stabilizing role in the market, with significant buybacks and continuous increases guiding market trends [2][3]. - Cross-border buybacks have emerged as a new highlight, as demonstrated by China International Marine Containers Group's simultaneous buyback of A-shares and H-shares, reflecting recognition of company value [3].

Core Insights - The trend of share buybacks and major shareholder increases among Shenzhen-listed companies has become normalized due to policy support and corporate confidence in market development [2][4] - In 2025, a total of 424 buyback and increase plans were disclosed in the Shenzhen market, with buyback plans accounting for 288 and a maximum buyback amount of 82.725 billion yuan, while increase plans totaled 136 with a maximum amount of 31.521 billion yuan [2] - Since the launch of special loans for buybacks and increases, 383 companies and major shareholders have obtained loan commitment letters totaling 82.981 billion yuan [2] Industry Distribution - Companies in the electronics, biomedicine, machinery, and power equipment sectors have become the main force in buybacks, accounting for 40.97% of total activities [2] - The biomedicine, machinery, basic chemicals, and home appliances sectors lead in shareholder increases, making up 37.78% of the total [2] Company Actions - Leading companies are acting as "ballast stones" in the market through significant buybacks and continuous increases [2] - Midea Group (000333) has launched a second buyback plan based on confidence in its future development, with total buybacks exceeding 10 billion yuan, enhancing shareholder equity and binding core team interests [2] - Contemporary Amperex Technology Co., Ltd. (300750) plans to repurchase shares totaling between 4 billion and 8 billion yuan, with a cumulative buyback amount of 4.386 billion yuan, reflecting its industrial ambitions [3] - Mindray Medical (300760) saw its chairman increase shares by 200 million yuan, demonstrating recognition of the company's intrinsic value [3] Cross-Border Buybacks - Cross-border buybacks have emerged as a new highlight, with China International Marine Containers (000039) disclosing simultaneous buybacks of A-shares and H-shares, showcasing recognition of company value [3] Market Outlook - The buyback and increase activities of listed companies reflect a rational recognition of their own value and the gradual emergence of long-term investment value in the capital market [4] - With ongoing market reforms and regulatory improvements, leading companies are expected to continue exerting a strong "driving effect," supporting the sustained positive trend of buybacks and increases in the Shenzhen market [4]